Efalizumab-induced bullous pemphigoid

J Am Acad Dermatol. 2010 Jan;62(1):161-162. doi: 10.1016/j.jaad.2009.02.031.

Authors

Tu Anh Duong¹, Valérie Buffard², Chantal André³, Nicolas Ortonne⁴, Jean Revuz², Martine Bagot², Jean-Claude Roujeau²

Affiliations

¹ Department of Dermatology, Hôpital Henri Mondor, Université Paris, Créteil, France. Electronic address: tu-anh.duong@hmn.aphp.fr.
² Department of Dermatology, Hôpital Henri Mondor, Université Paris, Créteil, France.
³ Department of Immunology, Hôpital Henri Mondor, Université Paris, Créteil, France.
⁴ Department of Pathology, Hôpital Henri Mondor, Université Paris, Créteil, France.

PMID: 20082902
DOI: 10.1016/j.jaad.2009.02.031

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal / adverse effects*
Antibodies, Monoclonal, Humanized
CD11 Antigens / administration & dosage
CD11 Antigens / adverse effects*
Glucocorticoids / therapeutic use
Humans
Male
Middle Aged
Pemphigoid, Bullous / chemically induced*
Pemphigoid, Bullous / drug therapy
Psoriasis / drug therapy

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
CD11 Antigens
Glucocorticoids
efalizumab